Filing Flows

Filing Flows › Cytokinetics (CYTK) › Next earnings date

Cytokinetics (CYTK) earnings: beat the estimate

Cytokinetics (CYTK) reported on Nov 4, 2026 and beat the EPS estimate: −$1.37 against −$1.41 (+2.6%). Revenue was $47.6M for Q3 2026, 25× year over year. It beat the EPS estimate in 60% of the quarters on record.

Last result+2.6% vs estimate
Beat rate60%

The last report

Cytokinetics reported revenue of $47.6M for the third quarter 2026 (25× Y/Y), net loss $190M: Net Product Revenue $44.5M, Collaboration Revenues $3.0M. How it makes money → · Every quarter →

Cytokinetics: EPS against the estimate, last 5 reportsCytokinetics: EPS against the estimate, last 5 reportsEstimateReported−$1.57−$1.54Nov 25−$1.37−$1.50Feb 26−$1.65−$1.67May 26−$1.60−$1.50Aug 26−$1.41−$1.37Nov 26
Latest (Nov 26): Estimate −$1.41, Reported −$1.37.
CYTK: the stock's move on each reportCYTK: the stock's move on each reportAug 6, 2026-2.7%May 5, 2026+13.3%Feb 24, 2026-7.9%Nov 5, 2025+1.1%

Cytokinetics' latest quarter

Cytokinetics, Q3 2026: revenue $47.6M (25× year over year), operating margin -351.3%, net loss $190M, operating cash flow −$124M. The chart follows the revenue to costs, profit and cash.

Questions

Did Cytokinetics beat earnings?

Cytokinetics (CYTK) reported on Nov 4, 2026 and beat the EPS estimate: −$1.37 against −$1.41 (+2.6%).

When does CYTK report earnings?

The next date is not set yet.

Does Cytokinetics usually beat earnings?

It beat the consensus EPS estimate in 60% of the quarters on record.

Open the interactive view →

Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.